6505--Carvedilol Tablets (VA-25-00048048)
ID: 36E79725R0028Type: Solicitation
AwardedJul 8, 2025
$18.4M$18,365,301
AwardeeGOLDEN STATE MEDICAL SUPPLY, INC. CAMARILLO 93012-8601
Award #:36E79725D0042
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/13329b757f504e418c203c84bc970795/view
Timeline
    Description

    The Department of Veterans Affairs is soliciting proposals for the supply of Carvedilol Tablets under solicitation number 36E79725R0028, with an amendment extending the submission deadline to May 1, 2025, at 2:30 PM Central Daylight Time. Offerors are required to provide pricing for various types of Carvedilol Tablets, submit unique National Drug Code (NDC) numbers, and comply with federal regulations, including the Drug Supply Chain Security Act (DSCSA) and FDA manufacturing standards. This procurement is crucial for ensuring a reliable supply of pharmaceuticals to enhance healthcare services for veterans and active duty military personnel. Interested contractors should direct their proposals to the specified VA email addresses and acknowledge receipt of the amendment to remain eligible for consideration.

    Point(s) of Contact
    Adrienne A AlbachiaraContracting Officer
    Adrienne.Albachiara@va.gov
    Files
    Title
    Posted
    36E79725R0028_1.docx
    The Department of Veterans Affairs (VA) intends to issue a Request for Proposal (RFP) for Carvedilol Tablets under solicitation number 36E79725R0028, aimed at ensuring uninterrupted supply for VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract will span one year, with four optional one-year extensions. Offerors must supply drugs labeled under their unique National Drug Code (NDC) and cannot replace existing labels on the products. The RFP is set to be electronically issued around March 19, 2025, with a response deadline of April 2, 2025. The anticipated annual requirements include various package sizes and dosages of Carvedilol tablets, with total estimated usage specified for each variant. Interested bidders need to monitor the SAM.gov for updates regarding the solicitation, and inquiries can be directed to the provided contact. This pre-solicitation notice outlines the VA's procurement process for a critical medication, emphasizing the need for a reliable supplier to support federal health care operations, thereby highlighting the commitment to serving veterans and affiliated populations through effective procurement practices.
    36E79725R0028.docx
    The document is a solicitation issued by the Department of Veterans Affairs for pharmaceutical supply under the Veterans Affairs and Department of Defense Pharmaceutical Prime Vendor Programs. It outlines the requirements for offers regarding various types of Carvedilol Tablets over a specified contracting period, including a base year and four option years. Offerors are required to submit pricing for all line items, provide unique National Drug Code (NDC) numbers, and ensure compliance with applicable regulations, including the Drug Supply Chain Security Act (DSCSA). Key points include the establishment of a business-to-business agreement with Prime Vendors and mandatory reporting of sales, along with a 0.5% Cost Recovery Fee. The document stresses compliance with FDA manufacturing standards and strong emphasis on the need for a Letter of Commitment from manufacturers for distributors. It specifies the seamless delivery process and the detailed steps for proposal submissions, performance assessments, and invoicing procedures. Overall, the document is a structured solicitation that aims to secure a reliable source for pharmaceuticals while ensuring compliance with federal regulations and requirements for government contracting, reflecting the intent to enhance healthcare services for veterans and active duty military personnel.
    36E79725R0028 0001.docx
    The document serves as an amendment to Request for Proposal (RFP) number 36E79725R0028, issued by the Department of Veterans Affairs for the provision of Carvedilol Tablets. The primary purpose of this amendment is to extend the deadline for offer submissions to May 1, 2025, at 2:30 PM Central Daylight Time. It instructs all bidders to submit their proposals to specified VA email addresses and outlines the importance of acknowledging receipt of the amendment. The amendment also emphasizes that all previously stated terms and conditions, aside from the due date alteration, remain unchanged and in effect. This document is vital for ensuring that potential contractors have adequate time to prepare and submit their offers, reflecting the federal government’s structured approach to procurement while complying with regulatory guidelines.
    Lifecycle
    Title
    Type
    6505--Carvedilol Tablets
    Currently viewing
    Award
    6505--Carvedilol Tablets (VA-25-00048048)
    Solicitation
    6505--Carvedilol Tablets (VA-25-00048048)
    Presolicitation
    Similar Opportunities
    COLESTIPOL HCL 1GM TAB and DESONIDE 0.05% CREAM - 762 TUCSON
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is conducting a Sources Sought Notice to identify potential qualified domestic sources for the procurement of COLESTIPOL HCL 1GM TAB and DESONIDE 0.05% CREAM through its National CMOP Office. This announcement serves as a market research tool rather than a solicitation, aiming to gather information on vendors' capabilities to meet the requirements outlined in the Statement of Requirements. The products sought are critical for pharmaceutical preparation and will support the healthcare needs of veterans. Interested vendors must submit their responses, including company details and capability statements, via email to Jennifer Coleman at Jennifer.Coleman4@va.gov by December 19, 2025, at 3:00 PM CDT. This notice does not obligate the VA to issue a solicitation.
    760-25-1-050-0154 -Leavenworth CMOP THYROID TABLETS -(VA-25-00022614)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for the procurement of Armour Thyroid tablets for the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) under solicitation number 36C77025Q0079. This Request for Quotation (RFQ) emphasizes the need for specific brand-name pharmaceuticals, with a focus on compliance with federal regulations, including the Drug Supply Chain Security Act and the Buy American Act. The procurement process aims to ensure a reliable supply of essential medications for veterans, with a firm-fixed-price contract expected to be awarded based on fair market evaluations. Interested vendors must submit their quotes by December 27, 2024, at 4:00 PM CST, and can direct inquiries to Jennifer L. Knight at jennifer.knight@va.gov or by phone at 913-684-0162.
    6505--36C77026Q0061/RFI/Domestic Sources Rx_MedSurge
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking information from domestic pharmaceutical manufacturers through a Request for Information (RFI) designated 36C77026Q0061, aimed at supporting the Consolidated Mail Outpatient Pharmacy (CMOP) in fulfilling its Open Market (OM) purchasing needs. The RFI seeks to identify both small and large businesses capable of providing a range of pharmaceutical products and ancillary items, with a focus on those manufactured in the United States, to enhance the supply chain for approximately 450,000 prescriptions mailed daily to Veterans. Interested manufacturers are required to submit detailed company and product information, including FDA-approved NDC numbers and operational capabilities, by March 15, 2026, at 4:30 PM CT. For further inquiries, respondents can contact Michael McAlhaney at Michael.McAlhaney@va.gov or (913) 684-1976.
    NATIONAL OPERATIONAL/MAILING SUPPLIES
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking proposals for operational and mailing supplies through solicitation number 36C77025R0004, aimed at supporting its seven Consolidated Mail Outpatient Pharmacy (CMOP) locations. This procurement involves establishing multiple National Single Award Indefinite Delivery/Indefinite Quantity (IDIQ) contracts for essential items such as corrugated boxes, bubble mailers, sealing tape, and child-resistant medical pouches, ensuring compliance with stringent specifications for patient safety and product integrity. The awarded contracts will facilitate timely deliveries of these supplies, which are critical for the efficient processing and shipment of prescriptions to veterans. Interested vendors must submit their proposals, including product samples and pricing schedules in Excel format, by the extended deadline of January 15, 2026, at 5:00 PM CDT. For further inquiries, contact Kelly L Mann at kelly.mann@va.gov or Kelley Cunningham at kelley.cunningham@va.gov.
    6505--Zonisamide Capsules
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified suppliers for a Firm Fixed Price, Indefinite-Delivery Requirements contract for Zonisamide Capsules in 25mg, 50mg, and 100mg dosages. Offerors are required to provide pricing for a base year and four option years, submit a 0.5% Cost Recovery Fee, and comply with stringent packaging and barcoding standards, including adherence to the Drug Supply Chain Security Act (DSCSA) and National Drug Code (NDC) requirements. These pharmaceutical products are crucial for the healthcare services provided to veterans and military personnel through the VA and DoD Pharmaceutical Prime Vendor Programs. Interested parties should contact Contract Specialist Christopher Carthron at Christopher.Carthron@va.gov for further details, and ensure they meet all compliance and registration requirements, including current SAM registration.
    6505--Ustekinumab Pens/Syringes or Biosimilar
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Ustekinumab Pens/Syringes or Biosimilars, aimed at supplying various federal health entities including the Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract will be awarded for an initial period of one year, with the possibility of four additional one-year option periods, ensuring a consistent supply of these critical pharmaceutical products through the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must provide drugs with unique National Drug Code (NDC) numbers and ensure that any biosimilar products meet FDA licensing requirements, as outlined in the FDA Purple Book. The solicitation is expected to be released around January 12, 2026, with a tentative closing date of January 27, 2026; interested parties should direct inquiries to Chris Carthron at Christopher.Carthron@va.gov or (708) 786-4980.
    Pharmaceutical Repackaging Services for National CMOP (770)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for pharmaceutical repackaging services for the National Consolidated Mail Outpatient Pharmacy (CMOP) program. The contract, identified as 36C77026R0004, is a firm-fixed-price, indefinite-delivery agreement intended to support the repackaging of government-purchased oral solid pharmaceuticals into various bottle sizes for distribution to over 7 million veterans. The contract spans a five-year ordering period from February 1, 2026, to January 31, 2031, with a potential six-month extension, and has a minimum value of $20 million and a maximum value of $125 million. Interested contractors should contact Renee Kreutzer at renee.kreutzer@va.gov for further details and must submit their proposals by the specified deadlines, ensuring compliance with all relevant regulations and standards.
    6505--Nicotine Lozenges MINI (VA-26-00020754)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Nicotine Mini Lozenges, specifically under solicitation number 36E79726R0007. This contract aims to ensure an uninterrupted supply of nicotine lozenges for the VA, Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS), with a contract duration of one year and four optional one-year extensions. The estimated annual requirements include 166,791 bottles of 2mg lozenges and 138,276 bottles of 4mg lozenges, which will be distributed through the VA and DOD Pharmaceutical Prime Vendor Programs. Interested offerors should note that the solicitation will be electronically issued around December 18, 2025, with a tentative closing date of January 1, 2026, and can direct inquiries to Billy Fong at billy.fong@va.gov or by phone at 708-786-4992.
    Metaxalone Tablets
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the supply of Metaxalone 800 MG tablets, available in 100-count and 500-count bottles. This procurement aims to establish a requirements contract with estimated annual quantities for a base year and four option years, emphasizing the need for compliance with various federal acquisition regulations and ethical standards. Metaxalone is a critical medication used for muscle relaxation, making this contract vital for supporting military health services. Interested vendors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) between November 7 and December 7, 2025, by 3:00 PM EST. For further inquiries, contact Jeremy Brown at jeremy.brown@dla.mil or Jason Wray at Jason.wray@dla.mil.
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.